# Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

> **NCT00391053** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 3851 (actual)

## Conditions studied

- Orthomyxoviridae Infection
- Influenza
- Myxovirus Infection

## Interventions

- **BIOLOGICAL:** High-Dose Inactivated, Split-Virion Influenza Vaccine
- **BIOLOGICAL:** High-Dose Inactivated, Split-Virion Influenza Vaccine
- **BIOLOGICAL:** High-Dose Inactivated, Split-Virion Influenza Vaccine
- **BIOLOGICAL:** Inactivated, Split-Virion Influenza Vaccine

## Key facts

- **NCT ID:** NCT00391053
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-07
- **Final completion:** 2008-02
- **Target enrollment:** 3851 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391053, "Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00391053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*